Bowen Hanes & Co. Inc. Has $63.35 Million Position in Elanco Animal Health Incorporated $ELAN

Bowen Hanes & Co. Inc. raised its position in Elanco Animal Health Incorporated (NYSE:ELAN) by 0.9% in the 1st quarter, Holdings Channel.com reports. The firm owned 2,647,270 shares of the company’s stock after buying an additional 23,500 shares during the period. Elanco Animal Health makes up 1.6% of Bowen Hanes & Co. Inc.’s portfolio, making the stock its 29th biggest holding. Bowen Hanes & Co. Inc.’s holdings in Elanco Animal Health were worth $63,349,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in ELAN. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in Elanco Animal Health in the 1st quarter valued at approximately $2,065,000. Goldman Sachs Group Inc. grew its holdings in Elanco Animal Health by 104.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company’s stock worth $50,268,000 after acquiring an additional 2,445,872 shares during the last quarter. Empowered Funds LLC grew its holdings in Elanco Animal Health by 35.2% during the 1st quarter. Empowered Funds LLC now owns 15,835 shares of the company’s stock worth $166,000 after acquiring an additional 4,121 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Elanco Animal Health by 4.5% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,793,337 shares of the company’s stock valued at $18,830,000 after acquiring an additional 76,408 shares during the period. Finally, Arrowstreet Capital Limited Partnership increased its position in Elanco Animal Health by 2,006.9% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 310,383 shares of the company’s stock valued at $4,432,000 after acquiring an additional 295,651 shares during the period. 97.48% of the stock is owned by institutional investors and hedge funds.

Elanco Animal Health Trading Down 2.2%

ELAN opened at $24.78 on Friday. Elanco Animal Health Incorporated has a twelve month low of $13.39 and a twelve month high of $27.72. The company has a fifty day moving average of $23.91 and a 200-day moving average of $23.97. The stock has a market cap of $12.38 billion, a PE ratio of -49.56, a price-to-earnings-growth ratio of 1.66 and a beta of 1.68. The company has a quick ratio of 1.12, a current ratio of 2.16 and a debt-to-equity ratio of 0.60.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings results on Wednesday, May 6th. The company reported $0.40 EPS for the quarter, beating analysts’ consensus estimates of $0.34 by $0.06. Elanco Animal Health had a negative net margin of 4.95% and a positive return on equity of 7.42%. The business had revenue of $1.37 billion for the quarter, compared to analysts’ expectations of $1.28 billion. During the same quarter in the prior year, the firm posted $0.37 earnings per share. The business’s quarterly revenue was up 14.9% compared to the same quarter last year. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. On average, sell-side analysts predict that Elanco Animal Health Incorporated will post 1.11 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have recently commented on ELAN. Citigroup lifted their price target on shares of Elanco Animal Health from $30.00 to $31.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. Piper Sandler reaffirmed an “overweight” rating on shares of Elanco Animal Health in a research report on Monday, June 29th. TD Cowen lifted their target price on Elanco Animal Health from $31.00 to $32.00 and gave the stock a “buy” rating in a report on Thursday, June 18th. JPMorgan Chase & Co. upped their price target on Elanco Animal Health from $28.00 to $30.00 and gave the company an “overweight” rating in a research report on Thursday, May 7th. Finally, Wall Street Zen cut Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research note on Sunday, May 24th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Elanco Animal Health has a consensus rating of “Moderate Buy” and a consensus price target of $28.73.

Insider Activity at Elanco Animal Health

In other Elanco Animal Health news, CEO Jeffrey N. Simmons bought 4,971 shares of the stock in a transaction on Friday, May 15th. The stock was acquired at an average cost of $20.09 per share, for a total transaction of $99,867.39. Following the completion of the acquisition, the chief executive officer owned 171,971 shares in the company, valued at $3,454,897.39. This trade represents a 2.98% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Also, insider Rajeev A. Modi purchased 4,911 shares of the company’s stock in a transaction on Friday, May 15th. The stock was acquired at an average cost of $20.35 per share, for a total transaction of $99,938.85. Following the completion of the purchase, the insider owned 160,812 shares of the company’s stock, valued at approximately $3,272,524.20. This trade represents a 3.15% increase in their position. The SEC filing for this purchase provides additional information. Company insiders own 1.14% of the company’s stock.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.